https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-12 / J. Virol. 2016 06;90(11):5343-5352
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-12 / J. Virol. 2016 06;90(11):5343-53522016-05-12 00:00:002019-02-15 09:22:53Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-07 / Virus Res. 2016 08;221:23-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-07 / Virus Res. 2016 08;221:23-92016-05-07 00:00:002019-02-15 09:22:52Newcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-04-27 / J. Pharmacol. Sci. 2016 Sep;132(1):24-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-04-27 / J. Pharmacol. Sci. 2016 Sep;132(1):24-302016-04-27 00:00:002019-02-15 09:13:31Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-04-20 / Oncolytic Virother 2016;5:27-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-04-20 / Oncolytic Virother 2016;5:27-342016-04-20 00:00:002019-02-15 09:23:14Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-02-09 / Ther Adv Urol 2016 Jun;8(3):203-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-02-09 / Ther Adv Urol 2016 Jun;8(3):203-142016-02-09 00:00:002016-02-09 00:00:00Novel immunotherapeutic approaches to the treatment of urothelial carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-01-14 / World J. Gastroenterol. 2016 Jan;22(2):748-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-01-14 / World J. Gastroenterol. 2016 Jan;22(2):748-632016-01-14 00:00:002016-01-14 00:00:00Viro-immune therapy: A new strategy for treatment of pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-01-06 / Viruses 2016 Jan;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-01-06 / Viruses 2016 Jan;8(1)2016-01-06 00:00:002019-02-15 08:36:16Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-12-23 / Viruses 2015 Dec;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-12-23 / Viruses 2015 Dec;8(1)2015-12-23 00:00:002019-02-15 09:19:11Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-12-21 / J. Exp. Clin. Cancer Res. 2015 Dec;34:153
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-12-21 / J. Exp. Clin. Cancer Res. 2015 Dec;34:1532015-12-21 00:00:002019-02-15 09:22:50Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-12-16 / Mol. Cancer 2015 Dec;14:210
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-12-16 / Mol. Cancer 2015 Dec;14:2102015-12-16 00:00:002015-12-16 00:00:00Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model
